Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.


CSE:SONA - Post by User

Comment by Sandblaster1980on Oct 08, 2020 11:31pm
350 Views
Post# 31694042

RE:RE:RE:RE:HC approval we see $30.

RE:RE:RE:RE:HC approval we see $30.
Pandora wrote:
Sandblaster1980 wrote:
Pandora wrote:
In the meantime while the feet dragging continues for SONA this is announced:

TORONTO, ON / ACCESSWIRE / October 8, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Corporation") announced today that it has launched a saliva-based PCR test which is designed for easier collection of patient samples. Since May 2020, StageZero has been offering swab-based PCR tests and serology tests. It has now added saliva tests and will shortly introduce an antigen test and a full viral respiratory panel to its test offering.

Hmmmm will have to keep a eye on that. Going in my watchlist. Ive sold my position there earlier in the year. Too bad i would have been up large. Cant win them all. LOL




Keep in mind that SZLS did a 1 for 8 consolidation in mid-September so the pre-consolidation equitable price would be about 10 cents so you may have not missed much depending on what your buy in price was.


Oh didn't know that then I guess I didn't miss much.
<< Previous
Bullboard Posts
Next >>